Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Payables: 2019-2025

Historic Payables for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $18.7 million.

  • BridgeBio Pharma's Payables rose 39.95% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.0 million, marking a year-over-year increase of 74.90%. This contributed to the annual value of $9.6 million for FY2024, which is 9.73% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Payables of $18.7 million as of Q3 2025, which was down 28.44% from $26.1 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Payables high stood at $27.5 million for Q1 2025, and its period low was $3.9 million during Q2 2023.
  • In the last 3 years, BridgeBio Pharma's Payables had a median value of $10.7 million in 2023 and averaged $12.8 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Payables slumped by 60.62% in 2022, and later soared by 482.17% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Payables (Quarterly) stood at $11.9 million in 2021, then fell by 2.74% to $11.6 million in 2022, then dropped by 7.81% to $10.7 million in 2023, then dropped by 9.73% to $9.6 million in 2024, then skyrocketed by 39.95% to $18.7 million in 2025.
  • Its Payables was $18.7 million in Q3 2025, compared to $26.1 million in Q2 2025 and $27.5 million in Q1 2025.